5-Nitro-1H-indazole-3-carbonitrile

5-Nitro-1H-indazole-3-carbonitrile (DL0805) is a Rho kinase (ROCK) inhibitor with an IC50 of 6.67 μM for ROCK-I. 5-Nitro-1H-indazole-3-carbonitrile reduces Norepinephrine (HY-13715) -induced transient contraction and inhibits contraction induced by increasing external calcium in the endothelium-denuded rings of rat models. 5-Nitro-1H-indazole-3-carbonitrile has a vasorelaxant activity but high toxicity. 5-Nitro-1H-indazole-3-carbonitrile can be used for cardiovascular diseases, especially hypertension research[1][2].

Product Specifications

CAS Number

[90348-29-1]

Product Name Alternative

DL0805

UNSPSC

12352005

Hazard Statement

H302-H315-H319

Target

ROCK

Related Pathways

Cell Cycle/DNA Damage; Cytoskeleton; Stem Cell/Wnt; TGF-beta/Smad

Field of Research

Cardiovascular Disease

Smiles

N#CC1=NNC2=C1C=C([N+]([O-])=O)C=C2

Molecular Formula

C8H4N4O2

Molecular Weight

188.14

Precautions

P264-P270-P280-P302+P352-P330-P362+P364-P501

References & Citations

[1]Yuan TY, et al. DL0805-2, a novel indazole derivative, relaxes angiotensin II-induced contractions of rat aortic rings by inhibiting Rho kinase and calcium fluxes. Acta Pharmacol Sin. 2016 May;37 (5) :604-16.|[2]Gong L, et al. The vasorelaxant mechanisms of a Rho kinase inhibitor DL0805 in rat thoracic aorta. Molecules. 2012 May 18;17 (5) :5935-44.